Expression of angiogenic chemokines in ovarian clear cell carcinoma

Journal of Obstetrics and Gynaecology Research

Volumn 39, Issue 1, 2013, Pages 297-304

  Quattrocchi, Livia ^a   Sisson, Melanie ^a   Green, Andrew ^b   Martin, Stewart G ^b   Durrant, Lindy ^b   Deen, Suha ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Chemokines; Chemotherapy in gynecological cancer; Clear cell carcinoma; Epithelial cancer of the ovary; Ovary; Vascular endothelial growth factor

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; STROMAL CELL DERIVED FACTOR 1; VASCULOTROPIN;

ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CLEAR CELL CARCINOMA; DISEASE SEVERITY; EARLY CANCER; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARIAN CLEAR CELL CARCINOMA; OVARY CARCINOMA; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TISSUE MICROARRAY;

ADENOCARCINOMA, CLEAR CELL; CHEMOKINE CXCL12; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; OVARIAN NEOPLASMS; RECEPTORS, CXCR4; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84875725043     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/j.1447-0756.2012.01949.x     Document Type: Article

References (26)

1. Pather S, Quinn MA. Clear-cell cancer of the ovary -is it chemosensitive? Int J Gynecol Cancer 2005; 15: 432-437.
2. Sugiyama T, Kamura T, Kigawa J et al. Clinical characteristics of clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000; 88: 2584-2589.
3. Goff BA, Sainz de la Cuesta R, Muntz HG et al. Clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 1996; 60: 412-417.
4. Ho CM, Huang YJ, Chen TC et al. Pure-Type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-Type advanced disease. Gynecol Oncol 2004; 94: 197-203.
5. Kobel M, Kalloger SE, Carrick J et al. A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol 2009; 33: 14-21.
6. Jiang YP, Wu XH, Xing HY, Du XY. Role of CXCL12 in metastasis of human ovarian cancer. Chin Med J (Engl) 2007; 120: 1251-1255.
7. Duncan TJ, Al-Attar A, Rolland P et al. Vascular endothelial growth factor expression in ovarian cancer: A model for targeted use of novel therapies? Clin Cancer Res 2008; 14: 3030-3035.
8. Eisenhauer EA, Therasse P, Bagaerts J et al. New response evaluation criteria in solid tumors: Revised RECIT guideline (Version 1.1). Eur J Cancer 2009; 45: 228-247.
9. Tavasolli FA, Devilee P. World Health Organization Classification of Tumors, Tumors of the Breast and the Female Genital Organs. Lyon: IARC Press, 2003.
10. Kononen J, Bubendorf L, Kallioniemi A et al. Tissue microarrays for high-Throughput molecular profiling of tumor specimens. Nat Med 1998; 4: 844-847.
11. Rosen DG, Huang X, Deavers MT, Malpica A, Silva EG, Liu J. Validation of tissue microarray technology in ovarian carcinoma. Mod Pathol 2004; 17: 790-797.
12. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000; 80: 1943-1949.
13. Shibata D, Martin J, Arnheim N. Analysis of DNA sequences in forty-year-old paraffin-embedded thin-Tissue sections: A bridge between molecular biology and classical histology. Cancer Res 1988; 48: 4564-4566.
14. McCarty KS Jr, Miller LS, Cox EB, Konrath J, McCarty KS Sr. Estrogen receptor analyses. Correlation of biochemical and immuno-histochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985; 109: 716-721.
15. Camp RL, Dolled-Filhart M, Rimm DL. X-Tile: A new bioinformatics tool for biomarker assessment and outcomebased cut-point optimization. Clin Cancer Res 2004; 10: 7252-7259.
16. Crozier M, Copeland L, Silva E, Gershenson DM, Stringer CA. Clear cell carcinoma of the ovary: A study of 59 cases. Gynaecol Oncol 1989; 35: 199-203.
17. Seidman J, Yemelyanova A, Khedmati F et al. Prognostic factors for stage I ovarian carcinoma. Int J Gynecol Pathol 2009; 29: 1-7.
18. Gilks CB. Molecular abnormalities in ovarian cancer subtypes other than high-grade serous carcinoma. J Oncol 2010; 2010: 1-7. Article ID 740968
19. DeLair D, Oliva E, Köbel M, Macias A, Gilks CB, Soslow RA. Morphologic spectrum of immunohistochemically characterized clear cell carcinoma of the ovary: A study of 155 cases. Am J Surg Pathol 2011; 35: 36-44.
20. Mabuchi S, Kawase C, Altomare DA et al. VEGF is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary. Mol Cancer Ther 2010; 9: 2411-2422.
21. Yoo-Young L, Tae-Joong K, Min-Ji K et al. Prognosis of ovarian clear cell carcinoma compared to other histological subtypes: A meta-Analysis. Gynecol Oncol 2011; 122: 541-547.
22. Mackay HJ, Brady MF, Oza AM et al., and on behalf of the Gynecologic Cancer InterGroup. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer 2010; 20: 945-952.
23. Jenison EL, Montag AG, Griffiths CT et al. Clear cell adenocarcinoma of the ovary: A clinical analysis and comparison with serous carcinoma. Gynecol Oncol 1989; 32: 65-71.
24. Kennedy AW, Biscotti CV, Hart WR, Webster KD. Ovarian clear cell adenocarcinoma. Gynecol Oncol 1989; 32: 342-349.
25. Itamochi H, Kigawa J, Sugiyama T, Kikuchi Y, Suzuki M, Terakawa N. Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol 2002; 100: 281-287.
26. Trimble EL, Fountain J, Birrer MJ. Recommendations of the 2005 ovarian cancer state of the science meeting. Gynecol Oncol 2006; 103: S26.